Development and characterization of long-acting darifenacin intravaginal ring for managing overactive bladder in women: harnessing QbD approach

Abstract Background The oral administration of darifenacin hydrobromide (DBr) is associated with low bioavailability of 15–19% due to poor solubility and extensive first-pass metabolism. Additionally, the conventional oral formulation results in poor patient compliance due to frequent administration. By designing an intravaginal ring as a sustained release formulation for the treatment of an overactive bladder, the present investigation aims to explore an alternate method of drug administration. Methods Intravaginal ring of matrix design was prepared comprising of DBr incorporated in polyurethane as biodegradable polymer, by injection molding technique. Intravaginal rings were evaluated for dimensional analysis, tensile strength, percent compression, drug content, in vitro drug release studies and accelerated stability studies. A 3 2 factorial design was employed to optimize the formulation, by taking quantity of polymer and plasticizer concentration as the critical material attribute and tensile strength, T50% and T90% as the critical quality attributes. Numerical and graphical optimization was carried out for optimization of vaginal ring. Tolerability of IVR was assessed on vaginal tissues, and cytotoxic evaluations were made on HeLa cell line. Results The tensile strength, percent compression and drug content at the end of 21 days for the optimized IVR were found to be 5.78 ± 0.4 MPa, 86.82 ± 5.1% and 95.44 ± 2.3%, respectively, and cumulative drug release T50% and T90% was 10.33 and 20.71 days. Under storage conditions, the accelerated stability assessment revealed little-to-no changes. The developed IVR exhibited biocompatibility and absence of any significant cytotoxicity. Conclusion The study highlights the possibility of intravaginal delivery as an alternative route for DBr administration that is stable and efficacious, and provides prolonged release. The user-centric delivery system underscores the broader potential of intravaginal delivery systems for addressing unmet needs in women's health. Graphical abstract

Authors

Institutions

Publication Details

Journal
Future Journal of Pharmaceutical Sciences
Published
2025-06-02
DOI
https://doi.org/10.1186/s43094-025-00820-8
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and characterization of long-acting darifenacin intravaginal ring for managing overactive bladder in women: harnessing QbD approach

Pranav Shah, Manisha S. Lalan, Maanika Menon, Guno Sindhu Chakraborthy
Future Journal of Pharmaceutical Sciences
Urinary Bladder and Prostate Research
article

Development and characterization of long-acting darifenacin intravaginal ring for managing overactive bladder in women: harnessing QbD approach

Pranav Shah, Manisha S. Lalan, Maanika Menon, Guno Sindhu Chakraborthy
article en

Abstract

Abstract Background The oral administration of darifenacin hydrobromide (DBr) is associated with low bioavailability of 15–19% due to poor solubility and extensive first-pass metabolism. Additionally, the conventional oral formulation results in poor patient compliance due to frequent administration. By designing an intravaginal ring as a sustained release formulation for the treatment of an overactive bladder, the present investigation aims to explore an alternate method of drug administration. Methods Intravaginal ring of matrix design was prepared comprising of DBr incorporated in polyurethane as biodegradable polymer, by injection molding technique. Intravaginal rings were evaluated for dimensional analysis, tensile strength, percent compression, drug content, in vitro drug release studies and accelerated stability studies. A 3 2 factorial design was employed to optimize the formulation, by taking quantity of polymer and plasticizer concentration as the critical material attribute and tensile strength, T50% and T90% as the critical quality attributes. Numerical and graphical optimization was carried out for optimization of vaginal ring. Tolerability of IVR was assessed on vaginal tissues, and cytotoxic evaluations were made on HeLa cell line. Results The tensile strength, percent compression and drug content at the end of 21 days for the optimized IVR were found to be 5.78 ± 0.4 MPa, 86.82 ± 5.1% and 95.44 ± 2.3%, respectively, and cumulative drug release T50% and T90% was 10.33 and 20.71 days. Under storage conditions, the accelerated stability assessment revealed little-to-no changes. The developed IVR exhibited biocompatibility and absence of any significant cytotoxicity. Conclusion The study highlights the possibility of intravaginal delivery as an alternative route for DBr administration that is stable and efficacious, and provides prolonged release. The user-centric delivery system underscores the broader potential of intravaginal delivery systems for addressing unmet needs in women's health. Graphical abstract

Future Journal of Pharmaceutical SciencesVol. 11(1)
Maharaja Sayajirao University of Baroda (IN), Uka Tarsadia University (IN), Parul University (IN)
Openalex Percentile: Top 82%
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.